Objective: Pregnancy is a unique situation characterized by insulin resistance. The role of adiponectin, an insulin-sensitizing hormone, has not been completely clarified during pregnancy. The aim of this cross-sectional study was to evaluate adiponectin levels during pregnancy and postpartum.
Introduction
Pregnancy is a unique situation in which there is a physiological, temporary, increase in insulin resistance. [1] [2] [3] The mechanisms responsible for the gestational-induced insulin resistance are not completely understood; however, previous studies suggested that increased concentrations of several hormones, including estrogen, progesterone, cortisol and human placental lactogen are plausible mediators of insulin resistance during pregnancy. 4 Lately, studies have implicated that adipocytokines, such as tumor necrosis factor alpha (TNF)-a) and leptin, are probable regulators of insulin resistance in pregnancy. 5 Adiponectin is an adipocytokine produced abundantly and exclusively in adipose tissue. A large body of evidence from experimental and epidemiological studies in adults has supported the important role of adiponectin in regulating insulin resistance and glucose homeostasis. The important metabolic effects of adiponectin as well as the growing evidences regarding the role of adipocytokines in the regulation of insulin sensitivity during pregnancy makes this hormone a conceivable candidate as a regulator of insulin resistances during pregnancy. Despite the important role of this hormone in the regulation of insulin sensitivity in physiological and pathological conditions, little is known about the role of this hormone during pregnancy. Although there are several studies concerning the association between adiponectin and gestational diabetes [6] [7] [8] [9] [10] or pre-eclampsia, [10] [11] [12] only few studies focused their attention on studying normal pregnant subjects. Moreover, there is only one study regarding adiponectin levels during pregnancy and as far as we are aware there are no comparative studies of adiponectin concentrations between the different trimesters and the immediate postpartum period. In order to evaluate whether there are alterations in adiponectin concentration throughout pregnancy, we determined adiponectin levels during first, second and third trimester and compared these levels to the immediate postpartum concentration of this hormone.
Material and methods

Subjects
Eighty healthy pregnant women were included in the study: 20 different set of patients from each trimester of pregnancy and 20 women 4 days post-partum. Given the cross-section nature of this study, our study population was carefully selected: the four groups were matched for age, pre-conception body mass index (BMI), gravity, parity, smoking status, number of fetuses and family history of diabetes (Table 1) . These parameters may affect adiponectin levels.
Gestational diabetes (GDM) was ruled out in all patients by normal glucose challenge test (GCT) or normal oral glucose tolerance test (according to American College of Obstetricians and Gynecologists (ACOG) and Carpenter and Coustan criteria) in cases when GCT was abnormally high. All subjects had normal GCT or normal oral glucose tolerance test according to ACOG and Carpenter and Coustan criteria. Thus, we did not have to exclude from the study any of the subjects in the first or second trimester. These tests were performed between 25 and 29 gestation weeks.
Patients with pre-eclampsia, chronic hypertension or GDM in index pregnancy or previous pregnancies were excluded.
Blood samples were collected during routine blood tests performed at first or second trimester and before elective cesarean section. The indications for the operative deliveries were previous cesarean section, breech presentation or maternal request. Patients in third trimester were examined before cesarean section in order to rule out possibility of active labor. All mothers had an unremarkable operative and post-operative course. Blood samples from the postpartum group were collected 4 days after delivery. Before blood samples were collected, the weight and height were measured and BMI was calculated.
The protocol was approved by the Institutional Review Board at the Sheba Medical Center and all women provided written informed consent.
Methods
Serum obtained by centrifugation of maternal venous blood was immediately frozen and stored at À701C until further analysis. Adiponectin and leptin were determined using radioimmunoassay kits (Linco Research, Inc., St Charles, MO, USA). The sensitivity of the adiponectin assay was 1 ng/ml and the interassay coefficient of variation (CV) ranged from 6.9 to 9.3%. The sensitivity of the leptin assay was 0.5 ng/ml and the interassay CV ranged from 3 to 6%. To note, the laboratory was blinded to the origin of samples.
Mean adiponectin and leptin were compared among the different groups. We measured leptin levels because leptinlike adiponectin is an adipocytokines. However, as opposed to adiponectin this hormone was thoroughly investigated. Thus, by measuring the levels of this hormone we planned to validate our novel findings regarding adiponectin levels. The relationships between adiponectin and leptin, preconception body mass index, Gestational BMI and gestational age were analyzed.
Statistical analysis
Data are presented as means±s.d. Differences in measured variables among groups were assessed with a one-way analysis of variance . Associations between continuous variables are described by correlation coefficients (Pearson and Spearman). Significance was accepted at P<0.05. Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS v. 11.5; SPSS Inc, Chicago, IL, USA).
Results
There were no significant differences between adiponectin levels in first (13. 3±3.6 mg/ml), second (12.6±4.4 mg/ml) and third trimester (11.2±3.7 mg/ml, Figure 1a) . However, postpartum adiponectin levels (8.8±2.1 mg/ml) were significantly lower as compared with first (P<0.0001), second (P<0.004) and third trimester (P<0.02). Leptin levels in second (23.6±10.8 ng/ml) and third trimester (30.2±13.3 mg/ml) were higher (P<0.02 and P<0.0001, respectively) as compared with postpartum levels (16.4±13.9 mg/ml). Leptin levels in first trimester (21.6±11.2 ng/ ml) were significantly lower as compared with third trimester (P<0.01, Figure 1b) .
As expected, adiponectin levels in first and second trimester were negatively correlated with preconception BMI (P<0.0001, r ¼ À0.7 and P<0.0006, r ¼ À0.5, respectively). However, no correlations were found between adiponectin levels in third trimester or postpartum levels and preconception BMI (P<0.3, r ¼ À0.2 and P<0.1, r ¼ À0.3, respectively). Leptin levels in second and third trimester, as well as postpartum levels were positively correlated with preconception BMI (P<0.002, r ¼ 0.7; P<0.005, r ¼ 0.5 and P<0.02, r ¼ 0.4, respectively).
There was no correlation between adiponectin and leptin during or after the pregnancy. No correlation was found between adiponectin levels and gestational BMI.
Comment
Similar to obesity, pregnancy is characterized by an increase in weight, body fat mass, insulin resistance and hypothalamic leptin resistance. 13 Indeed, during normal pregnancy, circulating levels of several adipocytokines like tumor necrosis factor alpha, 5 leptin 14 and resistin 15 rise. This increase in adipocytokines levels during Abbreviation: BMI, body mass index.
Adiponectin levels during pregnancy are steady S Mazaki-Tovi et al pregnancy may be implicated in the development of insulin resistance during pregnancy. Furthermore, recent studies found that the rise in TNF-a and leptin levels during pregnancy are correlated with the decline in insulin sensitivity. 5 These data are in accordance with levels of leptin reported in the present study.
Adiponectin is a novel adipocytokine produced abundantly and exclusively in adipose tissue. A large body of evidence from experimental and epidemiologic studies in adults has supported the important role of adiponectin in regulation of insulin sensitivity and glucose homeostasis. Furthermore, low adiponectin levels can predict the future development of insulin resistance, and elevated levels of this hormone have been shown to be protective against development of type II diabetes. 16 Consistent with the non-pregnant state, adiponectin levels are reduced in patients with GDM when compared with normal pregnant women. [6] [7] [8] [9] Moreover, lower first trimester adiponectin levels are predictive for the development of GDM later in pregnancy. 17 Finally, adiponectin levels during pregnancy are found to be negatively correlated with insulin resistance. 18 Despite gradual decrease in adiponectin along pregnancy, there is no significant alteration in adiponectin levels throughout pregnancy, even though insulin resistance is known to increase dramatically during gestation. A possible explanation for this alleged inconsistency may be an alteration in adiponectin regulation during gestation. Adiponectin expression and secretion have been shown to be subjected to regulation by numerous factors, some of which are possibly affected by the unique hormonal milieu of pregnancy. This hypothesis is supported by studies in mice, which suggest that estrogen, 19 prolactin 19 and testosterone 20 (all increased in normal human pregnancy) may affect adiponectin levels.
Moreover, as opposed to other physiological and pathological conditions, the reports regarding the correlation between adiponectin and insulin resistance during pregnancy are not consistent. 12, 18, 21, 22 Finally, BMI known to correlate positively with insulin resistance and negatively with adiponectin levels in the non-pregnant state. 23 Our group 24 and others found no correlation between adiponectin levels and BMI in pregnant individuals. 11, 12, 21 Thus, altered gestational regulation of adiponectin can explain the steady adiponectin levels throughout pregnancy found in this study.
The results of this study are in partial agreement with previous observations by Cseh et al., 6 which found similar mean adiponectin levels in the first trimester (12.3±3.2 mg/ml). However, in their study, adiponectin levels were lower during the second and third trimester. This discrepancy can be attributed to the lower number of participants in Cseh's study, and their younger age. In addition, no demographics were listed in that study.
Another interesting finding in this study is higher adiponectin levels during pregnancy as opposed to the postpartum period. Adiponectin levels during first second and third trimesters are significantly higher as compared with postpartum levels (P<0.0001, P<0.004 and P<0.02, respectively). These results are in agreement with previous observations by Kajantie et al.
11 who found lower levels of adiponectin in the postpartum period as compared with third trimester levels. One possible explanation for the higher levels of adiponectin measured during pregnancy may be an increase in adiponectin resistance. Hyperinsulinemic conditions, such as pregnancy, are associated with decreased number of adiponectin receptors, 25 thereby reducing adiponectin sensitivity and this may aggravate insulin resistance. The increase in insulin resistance may lead to compensatory increase in adiponectin levels. Another possible explanation for the reduced postpartum levels of adiponectin may be cessation of transport from the placenta. Although several investigators found placental expression of adiponectin, 26, 27 others failed to find the placenta as a novel site for adiponectin expression. 28 Given the controversy in the literature, we cannot rule out this possibility.
Our study has several limitations. We recognize that the crosssection nature as well as the relatively small number of subjects included in this study limits comment on causality in the association between pregnancy and regulation of adiponectin levels during pregnancy. However, in order to overcome the inherit limitations of such study, we carefully controlled our subjects for possible maternal parameters that may affect adiponectin levels (i.e., BMI, gestational diabetes, age and more).
In summary, lack of alteration in adiponectin levels during pregnancy may imply that adiponectin regulation is altered during gestation. The higher levels of adiponectin during pregnancy as compared with the postpartum period can support the notion of increased adiponectin resistance previously described only in hyperinsulinemic conditions not associated with pregnancy.
